washington new york  reuters    activist investor william ackman promised u s  lawmakers on wednesday that he will urge the board of valeant pharmaceuticals  vrx to  to reduce the high prices of four life saving drugs that are now at the heart of two congressional probes  speaking before the senate special committee on aging  ackman revealed that valeant s board will hold a conference call on thursday to discuss the costs of heart medications isuprel and nitropress  as well as cuprimine and syprine  two drugs that are used to treat a genetic disorder that causes copper to build up in the body s organs  valeant raised the price of isuprel by about  percent and nitropress by  percent  after acquiring them in   the other two were raised by   percent and   percent  respectively   my recommendation is going to be to reduce the prices   ackman testified  the senate special committee on aging is one of two u s  congressional panels investigating sky rocketing price increases of certain decades old drugs acquired by companies including valeant and turing pharmaceuticals  a company founded by martin shkreli  ackman  a major valeant shareholder  appeared wednesday alongside the company s outgoing chief executive michael pearson and howard schiller  a board member and former chief financial officer  ackman joined the board last month as valeant faced mounting scrutiny by members of congress  prosecutors and regulators over its drug pricing  business practices and accounting   issues that have caused its share price to plummet almost  percent since august  valeant has about   billion of debt and has been negotiating with creditors  some of whom issued notices of default after it missed a deadline for the filing of its financial results  ackman said wednesday that one of his top priorities is to protect the company from bankruptcy  later  in response to a question from reuters  he expressed confidence that the company will recover   there is not going to be any bankruptcy of valeant   he said   we were in a death spiral  and we have taken steps to deal with the banks  we are going to file our  on time  we brought in a new ceo   pearson  ackman and schiller all told lawmakers on wednesday they regretted valeant s pricing decisions   the company was too aggressive and i  as its leader  was too aggressive in pursuing price increases on certain drugs   he said  but many lawmakers on the panel appeared skeptical  they questioned valeant s business model of investing little in research and development  and the company s practice of acquiring decades old drugs and raising the prices  senator claire mccaskill  the panel s top democrat  angrily asked each of the panelists at one point if they could recall one drug that valeant didn t raise the price on    not in the united states   pearson responded  while schiller was only able to come up with the name of one drug valeant acquired after its purchase of salix   that is not social good  that is social bad   mccaskill said   lawmakers also questioned whether valeant s patient assistance and rebate programs are truly helping patients and hospitals afford the medications  senator susan collins  the panel s chairman  said her committee s investigation has thus far been unable to find a single hospital that has received a discount   i can assure you that many of the large hospital systems are getting discounts on the heart drugs   pearson said   pearson is expected to step down in the coming weeks to make way for the incoming ceo  joseph papa  previously of perrigo company  prgo n   wednesday s hearing also featured testimony from doctors and a patient with wilson s disease who was forced to stop using syprine because of the price spike   dr  frederick askari of the university of michigan told the panel that the cost of syprine is now so high that it has become less expensive to get a liver transplant and a life time supply of anti rejection medications  the patient  berna heyman  testified that valeant refused to help her when she called to complain about the prices  later  after speaking with the media  the company changed its tune  offered to help  and even sent flowers   i refused the flowers   she said  